Supernus Pharmaceuticals Inc (SUPN)
Operating return on assets (Operating ROA)
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating income (ttm) | US$ in thousands | 81,666 | 59,265 | 26,558 | -13,598 | -5,269 | 30,061 | 20,400 | 49,333 | 46,124 | 17,888 | 52,015 | 74,782 | 86,029 | 122,929 | 146,465 | 157,900 | 173,698 | 171,516 | 155,105 | 152,155 |
| Total assets | US$ in thousands | 1,368,070 | 1,342,700 | 1,315,830 | 1,304,090 | 1,277,670 | 1,285,160 | 1,293,100 | 1,791,810 | 1,702,510 | 1,693,130 | 1,694,970 | 1,639,520 | 1,689,150 | 1,555,040 | 1,573,060 | 1,507,440 | 1,504,100 | 1,510,020 | 1,491,020 | 1,189,870 |
| Operating ROA | 5.97% | 4.41% | 2.02% | -1.04% | -0.41% | 2.34% | 1.58% | 2.75% | 2.71% | 1.06% | 3.07% | 4.56% | 5.09% | 7.91% | 9.31% | 10.47% | 11.55% | 11.36% | 10.40% | 12.79% |
December 31, 2024 calculation
Operating ROA = Operating income (ttm) ÷ Total assets
= $81,666K ÷ $1,368,070K
= 5.97%
Supernus Pharmaceuticals Inc's operating return on assets (operating ROA) has been fluctuating over the analyzed period. The trend shows a gradual decline in the operating ROA from 12.79% in March 2020 to 5.97% in December 2024.
The company experienced a steady decrease in operating ROA throughout most of the period, with some fluctuations in between. There was a significant drop in operating ROA from September 2021 to March 2022, where it fell from 7.91% to 4.56%. The lowest point was observed in December 2023 and March 2024 where the operating ROA turned negative.
However, there was a slight recovery in the operating ROA towards the end of the period, with an increase from 2.02% in June 2024 to 5.97% in December 2024. This positive trend indicates a potential improvement in the company's operational efficiency and profitability.
In conclusion, the overall trend in Supernus Pharmaceuticals Inc's operating ROA shows variability and challenges in maintaining a consistent level of profitability over the analyzed period.
Peer comparison
Dec 31, 2024